Last: | $1.75 |
---|---|
Change Percent: | -1.11% |
Open: | $1.82 |
Close: | $1.75 |
High: | $1.82 |
Low: | $1.72 |
Volume: | 129,104 |
Last Trade Date Time: | 05/06/2024 03:00:00 am |
Quotes are delayed by 15 to 20 minutes.
Last | Open | Close | High | Low | Volume | Date |
---|---|---|---|---|---|---|
$1.75 | $1.82 | $1.75 | $1.82 | $1.72 | 129,104 | 05-06-2024 |
$1.8 | $1.81 | $1.8 | $1.84 | $1.76 | 162,062 | 05-03-2024 |
$1.76 | $1.78 | $1.76 | $1.8094 | $1.69 | 242,306 | 05-02-2024 |
$1.77 | $1.67 | $1.77 | $1.81 | $1.67 | 254,964 | 05-01-2024 |
$1.72 | $1.74 | $1.72 | $1.75 | $1.68 | 115,528 | 04-30-2024 |
$1.74 | $1.73 | $1.74 | $1.78 | $1.69 | 211,497 | 04-29-2024 |
$1.69 | $1.71 | $1.69 | $1.719 | $1.65 | 154,391 | 04-26-2024 |
$1.7 | $1.74 | $1.7 | $1.74 | $1.65 | 181,018 | 04-25-2024 |
$1.74 | $1.86 | $1.74 | $1.87 | $1.73 | 286,829 | 04-24-2024 |
$1.88 | $1.85 | $1.88 | $1.95 | $1.8101 | 209,626 | 04-23-2024 |
$1.82 | $1.71 | $1.82 | $1.84 | $1.6864 | 232,177 | 04-22-2024 |
$1.71 | $1.67 | $1.71 | $1.74 | $1.66 | 199,060 | 04-19-2024 |
$1.68 | $1.75 | $1.68 | $1.75 | $1.67 | 153,149 | 04-18-2024 |
$1.73 | $1.71 | $1.73 | $1.79 | $1.6701 | 169,880 | 04-17-2024 |
$1.71 | $1.8 | $1.71 | $1.83 | $1.7 | 350,333 | 04-16-2024 |
$1.8 | $1.92 | $1.8 | $1.98 | $1.755 | 304,227 | 04-15-2024 |
$1.9 | $2.03 | $1.9 | $2.04 | $1.87 | 224,800 | 04-12-2024 |
$2.04 | $1.98 | $2.04 | $2.06 | $1.94 | 182,277 | 04-11-2024 |
$1.97 | $2.03 | $1.97 | $2.0799 | $1.92 | 256,607 | 04-10-2024 |
$2.09 | $2.17 | $2.09 | $2.2 | $2.05 | 208,857 | 04-09-2024 |
News, Short Squeeze, Breakout and More Instantly...
Vor Biopharma Inc. Company Name:
VOR Stock Symbol:
NASDAQ Market:
CAMBRIDGE, Mass., May 02, 2024 (GLOBE NEWSWIRE) -- Vor Bio (NASDAQ:VOR), a clinical-stage cell and genome engineering company, today announced t...
CAMBRIDGE, Mass., May 02, 2024 (GLOBE NEWSWIRE) -- Vor Bio (Nasdaq: VOR), a clinical-stage cell and genome engineering company, today announced the appointment of Fouad Namouni, M.D., to its Board of Directors. Dr. Namouni currently serves as President of Research & Development at Blueprint M...
Trem-cel and VCAR33 ALLO clinical trial data expected in the second half of 2024 VCAR33 ALLO granted Fast Track and Orphan Drug Designation by U.S. Food & Drug Administration Cash runway extends into second half of 2025 CAMBRIDGE, Mass., March...